Latest Conference Coverage
Paving the Way for Autoimmune Neurology Treatment With CAR T-Cell Therapy: Amanda Piquet, MD, FAAN
February 28th 2025The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]
Unraveling Smoldering Multiple Sclerosis and Progressive Disability: Bruce Bebo, PhD
February 27th 2025The executive vice president of research at National MS Society discussed the role of compartmentalized inflammation, microglial interactions, and emerging therapeutic targets in multiple sclerosis. [WATCH TIME: 4 minutes]
Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS
February 27th 2025The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.
Notable Sessions to Eye Amid the 2025 ACTRIMS Forum: Véronique Miron, PhD
February 25th 2025The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]
Steps in Translating Genetic Discoveries Into Effective Treatments for ALS: Matthew B. Harms, MD
February 24th 2025The associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]
Nuances in Thrombectomy Techniques and Anesthesia Use for Stroke: J Mocco, MD, MS
February 23rd 2025The director of the Cerebrovascular Center at Mount Sinai discussed how results from the ESCAPE-MeVO trial highlight the impact of anesthesia rates, thrombectomy techniques, and the need for rigorous clinical trials to minimize bias. [WATCH TIME: 3 minutes]
Navigating the Future of Gene Therapy in Neuromuscular Disorders: John Brandsema, MD
February 20th 2025The pediatric neurologist at Children’s Hospital of Philadelphia provided background on a notable track session at the upcoming MDA Clinical & Scientific Conference covering updates in gene therapy for neuromuscular conditions. [WATCH TIME: 4 minutes]
Advancing Therapeutic Knowledge of Genetic Influence in ALS: Matthew B. Harms, MD
February 19th 2025The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]
ALS, Genetics, and New Horizons: What to Expect at the 2025 MDA Conference
February 18th 2025Matthew B. Harms, MD, an associate professor of neurology at Columbia University Irving Medical Center, an MDA Care Center, gave clinical insights on the advances in ALS genetic research and what clinicians can expect from the ALS/FTD track at the 2025 MDA Clinical & Scientific Conference.
Expanding the Development of Cell Therapy for Muscular Dystrophy: Rita Perlingeiro, PhD
February 18th 2025The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2025 conference. [WATCH TIME: 8 minutes]
Key Considerations When Incorporating Stroke Trial Data Into Clinical Practice: J Mocco, MD, MS
February 17th 2025The director of the Cerebrovascular Center at Mount Sinai highlighted key differences in patient selection criteria and trial designs that may influence how stroke treatment data is applied in clinical practice. [WATCH TIME: 5 minutes]
Advancements in Mechanical Thrombectomy and Imaging: A Stroke Neurologist’s Perspective
February 14th 2025Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.
Breaking Down ISC 2025: Key Takeaways From Experts in Stroke Neurology
February 13th 2025Stroke neurologists Lauren Sansing, MD, MS, FAHA, FANA, and Bijoy Menon, MD, MSc, FRCPC, provided a post-conference perspective on the emerging data and research presented at the 2025 International Stroke Conference.
NeuroVoices: Véronique Miron, PhD, on Exciting Developments and Expectations for ACTRIMS 2025
February 12th 2025The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.
Evaluating the Efficacy of Thrombectomy in Distal Vessel Occlusions: J Mocco, MD, MS
February 11th 2025The director of the Cerebrovascular Center at Mount Sinai talked about findings from recent trials presented at ISC 2025 investigating thrombectomy for distal vessel occlusions. [WATCH TIME: 4 minutes]
Evolution of Stroke Treatment on Display at ISC 2025: Andrei Alexandrov, MD
February 10th 2025The professor and chair of the neurology department at the University of Arizonia, Phoenix, gave clinical insights on the notable progress in the stroke treatment world, highlighted by advances presented at the 2025 International Stroke Conference. [WATCH TIME: 3 minutes]
Expanding the Time Window for Intravenous Thrombolysis in Ischemic Stroke: Min Lou MD, PhD
February 10th 2025The professor at the Second Affiliated Hospital of Zhejiang University’s School of Medicine discussed findings from a trial suggesting that intravenous thrombolysis could benefit patients with ischemic stroke up to 24 hours after symptom onset. [WATCH TIME: 8 minutes]
